Pharmacogenomics: road to anticancer therapeutics nirvana?

被引：0

作者：

Apurva A Desai

Federico Innocenti

Mark J Ratain

机构：

[1] The University of Chicago,Department of Medicine

[2] Committee on Clinical Pharmacology and Pharmacogenomics,undefined

[3] The University of Chicago,undefined

[4] Cancer Research Center,undefined

[5] The University of Chicago,undefined

来源：

Oncogene | 2003年 / 22卷

关键词：

pharmacogenomics; cancer chemotherapy; EGFR; irinotecan; thymidylate synthase;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Interindividual differences in the toxicity and response to anticancer therapies are currently observed for essentially all available treatment regimens. Such ‘unpredictable’ drug responses are particularly dangerous in the context of anticancer agents that have narrow therapeutic indices. Pharmacogenomics attempts to elucidate the inherited basis of interindividual differences in drug response, with the eventual goal of minimizing such variability through the use of ‘individualized’ treatments. There are several emerging examples of genetic polymorphisms of drug-metabolizing enzymes, DNA repair genes and drug targets that have been shown to influence the toxicity and efficacy of anticancer treatment. This review discusses the role of genetic variants of UGT1A1, TS and EGFR to exemplify the potential impact of phramacogenomics on the field of anticancer therapeutics.

引用

页码：6621 / 6628

页数：7